RXRX
RXRX clinical trials: RECURSION PHARMACEUTICALS, INC.
Every trial on ClinicalTrials.gov where RECURSION PHARMACEUTICALS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 10
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
RXRX on the catalyst calendar · RXRX registry changes
- Primary completion Jul 2029Sponsor estimatePhase 1/Phase 2NCT06678659A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic CancerRecursion Pharmaceuticals Inc. · UnresectableRecruitingRXRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2025ActualPhase 2NCT05085561The Symptomatic Cerebral Cavernous Malformation Trial of REC-994Recursion Pharmaceuticals Inc. · Cerebral Cavernous MalformationCompletedRXRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2031Sponsor estimatePhase 1/Phase 2NCT07819136REC-7735 in Participants With Solid TumorsRecursion Pharmaceuticals Inc. · Solid TumorsRecruitingRXRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 18, 2025ActualPhase 2/Phase 3NCT05130866Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated MeningiomasRecursion Pharmaceuticals Inc. · Neurofibromatosis Type 2TerminatedRXRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2028Sponsor estimatePhase 1NCT06980116Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell MalignanciesExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. · Relapsed or Refractory B-cell MalignanciesRecruitingRXRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2028Sponsor estimatePhase 1/Phase 2NCT05985655Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. · Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingRXRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2029Sponsor estimatePhase 1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. · Solid TumorRecruitingRXRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 1/Phase 2NCT05552755Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)Recursion Pharmaceuticals Inc. · Familial Adenomatous PolyposisRecruitingRXRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 24, 2025ActualPhase 2NCT06005974A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC MutationRecursion Pharmaceuticals Inc. · AXIN1 Gene MutationTerminatedRXRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 6, 2025ActualPhase 2NCT06536465The Clostridioides Difficile Trial of REC-3964Recursion Pharmaceuticals Inc. · Recurrent Clostridioides Difficile InfectionTerminatedRXRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner